Genetic Signatures

27 DIRECTORS’ REPORT FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 7 Name: Michael A Aicher Qualifications: BSc, MBA Experience: Mr. Aicher has over 30 years of industry experience and was CEO and founder of National Genetics Institute (NGI) which was acquired by Laboratory Corporation of America, Inc. (LabCorp) in 2000. Mr. Aicher led LabCorp’s Esoteric Business Units, which generated more than $1 billion in annual revenue. Prior to NGI, Mr. Aicher served in a number of executive leadership roles at Central Diagnostics Laboratory. He currently serves as a director on boards of Alveo Technologies, Techcyte and CytoBay. He is certified by the University of California at Berkeley as a Global Biotechnology Executive and is a recipient of Ernst & Young’s “Entrepreneur of the Year” award for emerging technologies. Mr. Aicher received a BS in Business Administration from the University of Redlands and an MBA in Economics from Columbus University. Special responsibilities: Executive Director – US Operations Directorships of other listed companies: Nil Interests in shares and options: 645,785 ordinary shares Company Secretary Name: Peter Manley Experience: Peter Manley was appointed Company Secretary of Genetic Signatures in March 2019. Peter is an experienced company secretary who also holds the position of Chief Financial Officer. Previous roles include CFO & Company Secretary for listed life sciences companies AtCor Medical Holdings Limited (now Cardiex Ltd) and Sirtex Medical Ltd. DIRECTORS’ MEETINGS The number of meetings of the board of directors (including board committees) held during the year ended 30 June 2021, and the numbers of meetings attended by each director are set out below: Board Audit & Risk Committee Nomination & Remuneration Committee Name Held Attended Held Attended Held Attended Nickolaos Samaras 8 8 2 2 2 2 John R Melki 8 8 - - - - Anthony J Radford 8 7 2 2 2 2 Michael A Aicher 8 8 - - - - Neil Gunn (appt. April 2021) 2 2 - - - - for the financial year ended 30 June 2021